Reading a COA and Chromatogram as Complementary Evidence

Two records can display the same purity percentage yet provide very different kinds of information. A certificate of analysis gives a structured account of reported tests and results. A chromatogram shows the detector response from a particular chromatographic run. Their value increases when the researcher can connect them to each other and to the supplied batch.

The purpose of comparing a COA with a chromatogram is not to choose the more impressive document. It is to determine whether the evidence is traceable, internally consistent and appropriate to the question being asked. A neatly formatted certificate or a visually simple trace cannot establish that on appearance alone.

This guide concerns evaluation of research-use peptide materials only. Neither type of record establishes suitability for human consumption.

First establish which sample the records describe

Before interpreting peaks or percentages, compare identifiers. The compound name and batch or lot number on the material should correspond to those on the COA. The chromatogram should carry a sample identifier that can be connected to that same batch.

Review dates as well. A report date and an analytical run date may refer to different stages of the reporting process, but the relationship should be understandable. An unexplained mismatch warrants clarification rather than an assumption that similarly named documents belong together.

A generic example can demonstrate how a laboratory presents its results. It cannot establish the characteristics of every later production lot. Traceability is therefore the foundation of the review: without it, even technically detailed data may concern a different sample.

The COA provides the reported testing framework

A certificate of analysis usually identifies the material and sets out tests, methods, specifications and results. Depending on the scope of analysis, it may include chromatographic purity, molecular mass information, peptide content, moisture, residual solvents or microbiological findings.

Not every COA includes all of these measurements. Their absence does not automatically establish poor material quality, but it does limit the conclusions that the report supports. If a research protocol requires a particular characteristic, do not infer it from an unrelated test.

Look for a clear distinction between the specification and the result. A specification describes the acceptance criterion; a result records what the analysis found. The testing laboratory or responsible quality-control function, method reference and report date should also be identifiable.

Method wording can change the meaning of a percentage. “HPLC purity by area normalisation” is more informative than “purity” alone because it names both the technique and the calculation basis. A reviewer still needs to understand what that calculation includes and excludes.

The chromatogram shows a separation, not a complete verdict

In chromatography, components pass through a column and interact differently with the stationary and mobile phases. The detector records a response as those components emerge. The resulting plot commonly places retention time on the horizontal axis and detector response on the vertical axis.

Peaks represent detected components under the method’s conditions. Their integrated areas may be used to calculate relative proportions. In an HPLC area-purity report, the principal peak’s area is compared with the total integrated area used in the calculation.

A COA might therefore state an HPLC purity result, while its associated chromatogram and peak table show the separation and areas behind that result. The certificate supplies the reported conclusion; the trace supplies part of the underlying evidence for one measurement.

However, a peak is not automatically a confirmed identity. Retention behaviour and a dominant signal need interpretation within the method and any supporting analytical evidence.

Read beyond the largest peak

A trace with one prominent peak can look convincing, but its meaning depends on the test conditions. Smaller peaks may represent related substances, degradation products, solvents or other detected components. Their interpretation requires context rather than visual judgement alone.

Detection wavelength is particularly relevant where UV detection is used. Different substances can produce different responses, and peptide absorption varies with amino-acid composition. A detector setting that reveals one component clearly may respond less strongly to another.

Integration also affects the reported areas. Software uses baseline placement, peak boundaries and integration rules to calculate each area. Poorly selected boundaries or treatment of minor signals can alter the apparent purity result.

For a meaningful review, seek a legible trace with a sample identifier, run date and peak-area table. Method information may include the column, mobile phases, gradient, flow rate and detection wavelength. A public-facing report may not reproduce an entire proprietary procedure, but missing context should be acknowledged as a limit on interpretation.

Understand what area normalisation measures

Area normalisation expresses an integrated peak area as a proportion of the total integrated peak area. It is a useful way to describe a chromatographic profile, but it is not necessarily an absolute mass measurement of every constituent.

Components may differ in detector response. Some may be poorly detected under the selected conditions, while others may not be separated adequately. The calculation therefore depends on both what the method reveals and how the signals are integrated.

Co-elution is another limitation. Two substances may leave the column at approximately the same time and appear as a single peak. Suitable method development aims to reduce this problem, but a clean-looking trace alone does not prove that it is absent.

For these reasons, HPLC purity should not be stretched into a claim about peptide content, complete sequence identity, biological activity, concentration in solution, sterility, endotoxin status or the absence of every contaminant. Those are separate analytical questions.

Identity testing answers a different question

Mass spectrometry can provide evidence consistent with an expected molecular mass by measuring mass-to-charge characteristics. That complements chromatographic information rather than duplicating it.

A material may show one dominant HPLC peak yet still need stronger identity support. Conversely, detecting a mass consistent with the intended peptide does not quantify its chromatographic purity. Neither finding, taken alone, is a comprehensive guarantee of sequence or overall suitability.

This is why orthogonal methods are valuable: they examine different properties of the sample. The strength of the evidence lies in how those findings fit together, not in accumulating test names without understanding their scope.

Reconcile the reported result with the trace

Once identifiers and methods are clear, compare the COA with the supporting peak table. If the certificate reports 98% HPLC area purity, the associated data should broadly show the relevant principal peak accounting for that proportion of the integrated total.

Minor differences may reflect rounding or presentation. A substantial discrepancy needs an explanation, especially if different traces, sample preparations or calculation conventions may have been used. The appropriate response is to request clarification rather than choose whichever number seems more favourable.

A practical review can follow four steps:

• Match the material, batch and analytical sample identifiers.
• Identify whether each result concerns purity, content, identity or another property.
• Compare the reported calculation with the supporting analytical data.
• Record missing information and decide whether further verification is required.

Independent testing may be appropriate where the research protocol demands a defined analytical standard. Supplier records remain useful, but they do not replace project-specific verification requirements.

Recognise incomplete or ambiguous reporting

Cropped axes, missing sample identifiers and absent peak tables can make a chart difficult to evaluate. A certificate stating only “tested” leaves the method and result unclear. These weaknesses matter because they prevent the reader from checking the claim, not merely because they make the document look unfinished.

It is also useful to distinguish supplier-issued certificates from independent laboratory reports. Either may contain valuable evidence. Independent analysis creates greater separation between supply and verification, but the same questions still apply: who tested the sample, when, by which method and from which batch?

For product-level context, the Cagrilintide research listing provides a starting point for reviewing the material offered and requesting relevant records. Researchers planning delivery to Hong Kong should distinguish analytical reporting from logistics: deliveries originate in Germany, the USA or China and take 5–18 business days from tracking, rather than departing from local premises.

Use both records without overclaiming either

The COA organises the formal findings; the chromatogram helps explain a particular separation. Together they can support a more informed assessment, provided their identifiers, methods and calculations align.

When reviewing available batch laboratory reports, start with the lot, then the method, then the result. Finish by asking what remains untested or uncertain. This sequence turns documentation into a practical research tool rather than a collection of reassuring images.